CLINICAL_TRIALS ClinicalTrials.gov record update

A Double-blinded Extension Study to Provide Adjuvant Treatment With Single Agent Herceptin® or TX05 and Assess Continued Safety and Immunogenicity in Subjects With HER2-positive Early Breast Cancer Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04109391
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:56.645139+00:00
Published At: 2022-10-26T00:00:00+00:00
Record Updated At: 2022-10-26
Results Posted At: 2022-10-26
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["HER2-positive Breast Cancer", "Early-stage Breast Cancer", "Breast Cancer", "Breast Neoplasms", "Stage II Breast Cancer", "Stage IIIA Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-10-26"
protocolSection.identificationModule.nctId: "NCT04109391"
protocolSection.identificationModule.officialTitle: "A Double-blinded Extension Study to Provide Adjuvant Treatment With Single Agent Herceptin\u00ae or TX05 and Assess Continued Safety and Immunogenicity in Subjects With HER2-positive Early Breast Cancer Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2022-10-26"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.